| Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC) |
|
|
| |
| • Company Description |
| Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Number of Employees: 6,223 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $9.61 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 98,348 shares |
| Shares Outstanding: 1,701.95 (millions) |
| Market Capitalization: $16,355.76 (millions) |
| Beta: 0.08 |
| 52 Week High: $12.00 |
| 52 Week Low: $7.83 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
4.46% |
5.56% |
| 12 Week |
1.48% |
-1.00% |
| Year To Date |
7.02% |
-4.41% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1-8 DOSHOMACHI 3-CHOME
-
OSAKA,M0 541-0045
JPN |
ph: 816-620-2216
fax: - |
None |
http://www.shionogi.com |
|
|
| |
| • General Corporate Information |
Officers
Isao Teshirogi - Chief Executive Officer
Keiichi Ando - Chairperson
John Keller - Director and Senior Executive Officer; Senior Vice
Hiroshi Ozaki - Director
Takaoki Fujiwara - Director
|
|
Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASIF)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 10/26/26
|
|
Share - Related Items
Shares Outstanding: 1,701.95
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.08
Market Capitalization: $16,355.76 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 1.45% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.18 |
Indicated Annual Dividend: $0.14 |
| Current Fiscal Year EPS Consensus Estimate: $0.82 |
Payout Ratio: 0.14 |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: -0.04 |
| Estmated Long-Term EPS Growth Rate: 3.38% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 10/26/26 |
|
|
|
| |
